Efficacy of High-Dose Oral Vitamin D3 as Monotherapy in the Management of Psoriasis (Code-T0235)

Background: Psoriasis is a chronic inflammatory skin disorder characterized by accelerated skin cell turnover. While several treatments are available, the search for effective and safe therapies continues. Vitamin D3 has been shown to play a significant role in regulating immune responses and skin cell proliferation, suggesting its potential as a therapeutic agent for psoriasis.

Aim and Objectives:

1. To detect the efficacy and assess safety of High dose oral Vitamin D3 (Cholecalciferol) as monotherapy in the management of Psoriasis
2. To look for any adverse events developed during therapy

Methods: A prospective study was conducted involving 100 patients diagnosed with moderate to severe psoriasis. Participants were administered high-dose oral vitamin D3 (4000 IU daily) for a period of 12 weeks. Psoriasis severity was measured using the Psoriasis Area and Severity Index (PASI) score before and after treatment. Clinical parameters, including skin appearance, scaling, and erythema, were also evaluated. Safety was monitored through regular assessments of calcium levels and kidney function.

Results: After 12 weeks of treatment, a significant reduction in PASI scores was observed in 75% of patients, with an average improvement of 40%. A notable reduction in erythema, scaling, and overall skin appearance was reported. No significant adverse effects were noted, although mild hypercalcemia was observed in a small subset of patients.

Conclusion: High-dose oral vitamin D3 appears to be an effective monotherapy for managing psoriasis, with significant clinical improvement in the majority of patients. It offers a safe and promising alternative treatment, particularly for those who may not tolerate other conventional therapies.

Keywords: Vitamin D3, psoriasis, monotherapy, high-dose treatment, Psoriasis Area and Severity Index (PASI), skin disorders.